CYP2C19 intermediate metabotropic symptomatic moderate to severe cerebral artery stenosis
Conditions
Interventions
test group:Double-antibody treatment for increasing clopidogrel dose
Control group:Conventional dose double antibody therapy
Sponsors
The Affiliated Yantai Yuhuangding Hospital of Qingdao University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Continuously enrolled patients with acute ischemic stroke; 2. Aged 40 to 75 years old; 3. Patients with ischemic stroke within 7 days of onset and with moderate to severe cerebral artery stenosis, and study drugs can be applied within 24 hours after enrollment; 4. CYP2C19 test prompts for patients with intermediate metabolites.
Exclusion criteria
Exclusion criteria: 1. Cranial MRI or brain CT confirmed non-cerebrovascular disease events; 2. There are obvious signs of anticoagulation (susceptive cardiogenic embolism, such as atrial fibrillation, known artificial heart valves, suspicious endocarditis, etc.); 3. Have gastrointestinal bleeding within 3.1 years or check fecal occult blood positive after admission; 4. History of intracranial hemorrhage (cerebral hemorrhage or subarachnoid hemorrhage); 5. Severe heart failure, asthma, liver and kidney dysfunction (defined as abnormal alanine aminotransferase and creatinine value); 6. History of previous coagulopathy or systemic hemorrhage, history of thrombocytopenia or neutropenia; 7. Leukopenia (5 days of treatment; 9. Patients who are pregnant or are participating in other clinical trials; 10. The patient or legal representative refuses to participate in the investigation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CYP2C19 gene detection; | — |
Countries
China
Contacts
Public ContactWu Hongliang
The Affiliated Yantai Yuhuangding Hospital of Qingdao University
Outcome results
None listed